小剂量左西替利嗪间歇疗法预防慢性荨麻疹复发的临床观察

Clinical Observation of Low-dose Levocetirizine Intermittent Treatment in Preventing the Recurrence of Chronic Urticaria

目的观察小剂量左西替利嗪间歇疗法预防慢性荨麻疹复发的疗效、长期用药的安全性以及生活质量改善情况。方法采用随机平行对照的临床试验,两组各50例。两组在急性发作期先予H1和H2受体拮抗剂联合治疗,待症状和体征完全改善后进行两组的治疗和观察。治疗组予小剂量左西替利嗪间歇治疗(2.5mg,隔天或每3天或每周给药1次);对照组不予药物间歇治疗,仅于发作时予H1和H2受体拮抗剂联合治疗。追踪观察1年。结果治疗组与对照组比较,复发率明显下降,有显著差异(P均<0.01)。且治疗组复发患者中症状、体征总和分明显低于对照组和治疗前,有显著差异(P均<0.01)。治疗后未见不良反应事件发生。两组患者生活质量差情况做比较,治疗组间歇治疗1年后生活质量差得到完全改善。结论小剂量左西替利嗪间歇治疗能有效、长期预防慢性荨麻疹的复发,且安全性好。常用剂量2.5mg,隔天或每3天1次或每周给药1次。

Objective To observe the effects of low-dose levocetirizine intermittent treatment on the recurrence,long-term safty and the quality of life of patients suffering from chronic unticaria（CU）. Methods One hundred patients with CU were randomly divided into two groups after all of them had been complete recovery in signs and symptoms with the co-administration of H1- antagonists ebastine and H2 - antagonists ebastine. The treatment group received a low - dose levocetirizine intermittent treatment （2.5 mg, every two days or every three days or every week） ; the control group, no intermittent treatment, only treated with the the co-administratlon of H1 -antagonists ebastine and H2-antagonists ebastine when CU relapsed. Follow-up visits 12 months to compared recurrence rate and assess long-term safty and the quality of life. Results Compared to that of the control group,there was a significant decrease of recurrence rate in the treatment group （ P 〈 0.01 ）. Total scores of the signs and symptoms in the treatment group were lower than that in the control group （P 〈 0.01 ）. No drug-related serious side-effects were associated with its long-term use. Patients with pool-quality of life were completely improved after 12 months of intermittent treatment. Conclusion Low-dose levocetirizine intermittent treatment is a new and safe and remarkably effective approach to the prevention of the recurrence of CU.